CapitalBio | GenomeWeb

CapitalBio

Fluidigm of South San Francisco, Calif., has received US Patent No.

CapitalBio and Tsinghua University of Beijing have received US Patent No.

The global adoption of microarrays for the detection of genetic abnormalities has continued into the new year, with Chinese life sciences company CapitalBio announcing recently the introduction of chromosomal microarray analysis services via its medical testing laboratories.

NEW YORK (GenomeWeb News) – Chinese life science company CapitalBio will solidify its efforts to become a major laboratory testing player in the country's clinical and consumer genetics markets by opening a new facility next year.

By law, Chinese samples cannot leave China. That fact has made Shanghai Biochip a partner for international pharmaceutical companies seeking to conduct various trials in the country.

BEIJING — Like many microarray vendors, CapitalBio sees future growth opportunities in molecular diagnostics.

CapitalBio and Tsinghua University, both of Beijing, have received US Patent No.

This article has been updated from a version posted Feb. 16 to include comments from an Affymetrix official.
By Justin Petrone

IP Roundup

Premium

Anagnostics, SRU Biosystems, Affymetrix, CapitalBio

Roche NimbleGen will work with Beijing-based CapitalBio to develop instruments and products to enhance and automate its microarray workflow for use in preventive and personalized diagnostics.

Pages

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.